ArticleVirology journal2025
Characterization and therapeutic evaluation of the lytic bacteriophage ENP2309 against vancomycin-resistant Enterococcus faecalis infections in a mice model.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Isolation and therapeutic potential of phage vB_EcoM_GXW16 against a drug-resistant avian pathogenic Escherichia coli strain.Poultry science · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe global emergence of vancomycin-resistant Enterococci (VRE) represents a growing threat to public health worldwide. To address this critical challenge, we isolated and characterized a novel lytic bacteriophage, ENP2309, from agricultural wastewater. Comprehensive analysis revealed distinct morphological features, biological properties, and genomic characteristics of ENP2309. Most notably, systematic evaluation in a mice infection model demonstrated significant in vivo therapeutic efficacy.
methodsBacteriophage isolation was performed using the double-layer agar method with the Enterococcus faecalis strain. Phage morphology was characterized by transmission electron microscopy (TEM), The host range was determined via plaque assays and the plating efficiency of multiple bacterial isolates. was evaluated double-layer agar method was systematically employed to evaluate thermal stability, pH tolerance, one-step growth kinetics, and the optimal multiplicity of infection (MOI) through plaque-forming unit (PFU) enumeration. The genomic features were analysed using next-generation sequencing. Furthermore, the therapeutic efficacy of phage ENP2309 against Enterococcal infection in mice was systematically evaluated through a comprehensive assessment of multiple parameters including body weight dynamics, survival rates, histopathological analysis, peripheral blood cytokine profiles, and bacterial loads in the spleen and liver tissues, demonstrating its multidimensional therapeutic effects.
resultsThe phage ENP2309 showed broad-spectrum lytic capability, effectively targeting 13 distinct Enterococcus clinical isolates. TEM revealed the morphology of ENP2309, featuring an icosahedral capsid (70 ± 1 nm in diameter) and a contractile tail structure (145 ± 2 nm in length). Comprehensive biological characterization revealed optimal infection parameters including an exceptionally low multiplicity of infection (MOI = 0.001), a 40-minute latent period, and an extended 40-120 min burst period resulting in a burst size of 920 PFU/cell. The phage exhibited environmental stability, maintaining infectivity across broad temperature (10-60 °C) and pH (3-12) ranges, with optimal activity observed at 37 °C and neutral pH (7.0-7.5). Genomic analysis revealed a 148,806 bp linear dsDNA (35.9% GC content) containing 153 putative ORFs. Phylogenetic classification revealed that ENP2309 a member of the Kochikohdavirus genus, is closely related to the Enterococcus phage PBEF129. In vivo studies demonstrated exceptional therapeutic potential: a single dose (200 µL 2.0 × 10⁸ PFU/mL) of phage ENP2309 achieved 100% survival in mice models, completely clearing VRE from the spleen and liver while significantly improving physiological parameters, reducing organ damage, and attenuating systemic inflammation.
conclusionsThese comprehensive findings establish ENP2309 as a highly promising therapeutic alternative to conventional antibiotics for VRE infections with distinct advantages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.